Aerie Pharmaceuticals Inc. (AERI) Rating Reiterated by Cantor Fitzgerald
Aerie Pharmaceuticals Inc. (NASDAQ:AERI)‘s stock had its “buy” rating reiterated by Cantor Fitzgerald in a research note issued to investors on Saturday. They presently have a $50.00 price objective on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 23.49% from the company’s current price.
Other research analysts also recently issued research reports about the company. Brean Capital set a $48.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, September 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 price target (up previously from $45.00) on shares of Aerie Pharmaceuticals in a research note on Thursday, September 15th. Stifel Nicolaus lifted their price target on Aerie Pharmaceuticals from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 15th. Zacks Investment Research raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Tuesday, July 12th. Finally, Royal Bank Of Canada lifted their price target on Aerie Pharmaceuticals from $51.00 to $55.00 and gave the stock an “outperform” rating in a research note on Thursday, September 15th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $51.40.
Aerie Pharmaceuticals (NASDAQ:AERI) opened at 40.49 on Friday. Aerie Pharmaceuticals has a 52 week low of $10.82 and a 52 week high of $41.72. The stock’s market cap is $1.13 billion. The firm’s 50-day moving average is $28.57 and its 200 day moving average is $19.49.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/08/aerie-pharmaceuticals-inc-aeri-rating-reiterated-by-cantor-fitzgerald.html
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.02. On average, equities research analysts expect that Aerie Pharmaceuticals will post ($2.81) EPS for the current year.
In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. sold 50,000 shares of Aerie Pharmaceuticals stock in a transaction dated Thursday, October 6th. The stock was sold at an average price of $40.34, for a total value of $2,017,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 8.77% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of the stock. Barclays PLC boosted its stake in Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock valued at $106,000 after buying an additional 200 shares during the period. ProShare Advisors LLC boosted its stake in Aerie Pharmaceuticals by 3.0% in the second quarter. ProShare Advisors LLC now owns 22,695 shares of the company’s stock valued at $399,000 after buying an additional 669 shares during the period. Tocqueville Asset Management L.P. boosted its stake in Aerie Pharmaceuticals by 1.7% in the second quarter. Tocqueville Asset Management L.P. now owns 42,300 shares of the company’s stock valued at $744,000 after buying an additional 725 shares during the period. Geode Capital Management LLC boosted its stake in Aerie Pharmaceuticals by 0.6% in the first quarter. Geode Capital Management LLC now owns 161,319 shares of the company’s stock valued at $1,961,000 after buying an additional 925 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its stake in Aerie Pharmaceuticals by 4.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 24,578 shares of the company’s stock valued at $433,000 after buying an additional 1,019 shares during the period. Institutional investors own 95.22% of the company’s stock.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.